pI: 5.4834 |
Length (AA): 629 |
MW (Da): 70273 |
Paralog Number:
1
Signal peptide: Y | GPI Anchor: | Predicted trans-membrane segments: 1
Targets have been classified into druggability groups (DG) according to their druggability score in network driven prioritizations. DGs range from 1 to 5; the higher the group number, the higher the chance of the target to be druggable
Modbase 3D models:
PDB Structures:
Upregulation Percent | Ranking | Stage | Dataset |
---|---|---|---|
Upper 60-80% percentile | Bloodstream Form. | Siegel TN |
Upregulation Percent | Ranking | Stage | Dataset |
---|---|---|---|
Mid 40-60% percentile | Procyclic. | Siegel TN |
Siegel TN | Genome-wide analysis of mRNA abundance in two life-cycle stages of Trypanosoma brucei and identification of splicing and polyadenylation sites. |
Ortholog group members (OG5_127162)
Species | Accession | Gene Product |
---|---|---|
Arabidopsis thaliana | AT4G30210 | NADPH--cytochrome P450 reductase 2 |
Arabidopsis thaliana | AT4G24520 | NADPH--cytochrome P450 reductase 1 |
Babesia bovis | BBOV_I002330 | flavodoxin and oxidoreductase NAD-binding domain containing protein |
Brugia malayi | Bm1_41510 | FAD binding domain containing protein |
Candida albicans | CaO19.2672 | NADP-cytochrome P450 reductase |
Candida albicans | CaO19.10187 | NADP-cytochrome P450 reductase |
Caenorhabditis elegans | CELE_K10D2.6 | Protein EMB-8 |
Cryptosporidium parvum | cgd4_2700 | probable NADPH-cytochrome p450 reductase |
Chlamydia trachomatis | CT_435 | sulfite reductase |
Dictyostelium discoideum | DDB_G0269912 | NADPH-cytochrome-P450 oxidoreductase |
Dictyostelium discoideum | DDB_G0293904 | NADPH-cytochrome-P450 oxidoreductase |
Drosophila melanogaster | Dmel_CG11567 | Cytochrome P450 reductase |
Escherichia coli | b2764 | sulfite reductase, alpha subunit, flavoprotein |
Echinococcus granulosus | EgrG_000797900 | NADPH cytochrome P450 reductase |
Echinococcus multilocularis | EmuJ_000797900 | NADPH cytochrome P450 reductase |
Giardia lamblia | GL50803_15897 | Hypothetical protein |
Homo sapiens | ENSG00000127948 | P450 (cytochrome) oxidoreductase |
Leishmania braziliensis | LbrM.28.1340 | p450 reductase, putative |
Leishmania donovani | LdBPK_281350.1 | p450 reductase, putative |
Leishmania infantum | LinJ.28.1350 | p450 reductase, putative |
Leishmania major | LmjF.28.1240 | p450 reductase, putative |
Leishmania mexicana | LmxM.28.1240 | p450 reductase, putative |
Loa Loa (eye worm) | LOAG_00956 | FAD binding domain-containing protein |
Mus musculus | ENSMUSG00000005514 | P450 (cytochrome) oxidoreductase |
Mycobacterium tuberculosis | Rv1394c | Probable cytochrome P450 132 Cyp132 |
Mycobacterium ulcerans | MUL_1474 | formate dehydrogenase H FdhF |
Neospora caninum | NCLIV_060990 | hypothetical protein |
Oryza sativa | 4345047 | Os08g0243500 |
Oryza sativa | 4347838 | Os09g0558900 |
Oryza sativa | 4337244 | Os04g0653400 |
Plasmodium berghei | PBANKA_0824100 | nitric oxide synthase, putative |
Plasmodium falciparum | PF3D7_0923200 | nitric oxide synthase, putative |
Plasmodium knowlesi | PKNH_0721200 | nitric oxide synthase, putative |
Plasmodium vivax | PVX_099570 | NADPH-cytochrome p450 reductase, putative |
Plasmodium yoelii | PY05179 | unnamed protein product-related |
Saccharomyces cerevisiae | YHR042W | Ncp1p |
Schistosoma japonicum | Sjp_0040140 | ko:K00327 NADPH-ferrihemoprotein reductase [EC1.6.2.4], putative |
Schistosoma japonicum | Sjp_0207040 | ko:K00327 NADPH-ferrihemoprotein reductase [EC1.6.2.4], putative |
Schistosoma mansoni | Smp_030760 | cytochrome P450 reductase |
Schmidtea mediterranea | mk4.001376.10 | NADPHALQ-cytochrome P450 reductase |
Schmidtea mediterranea | mk4.051841.00 | |
Schmidtea mediterranea | mk4.003471.02 | |
Trypanosoma brucei gambiense | Tbg972.11.9550 | NADPH--cytochrome p450 reductase, putative |
Trypanosoma brucei gambiense | Tbg972.11.8610 | NADPH--cytochrome p450 reductase, putative |
Trypanosoma brucei | Tb927.11.8380 | NADPH--cytochrome P450 reductase, putative |
Trypanosoma brucei | Tb11.02.5420b | NADPH-cytochrome p450 reductase, putative |
Trypanosoma congolense | TcIL3000_0_54440 | NADPH-cytochrome p450 reductase, putative |
Trypanosoma cruzi | TcCLB.506585.70 | p450 reductase, putative |
Toxoplasma gondii | TGME49_219630 | flavodoxin domain-containing protein |
Theileria parva | TP03_0092 | hypothetical protein |
Trichomonas vaginalis | TVAG_136330 | sulfite reductase, putative |
Trichomonas vaginalis | TVAG_483690 | NADPH fad oxidoreductase, putative |
Gene/Ortholog | Organism | Phenotype | Source Study |
---|---|---|---|
mtu1417 | Mycobacterium tuberculosis | non-essential | nmpdr |
Tb11.02.5420 | Trypanosoma brucei | significant loss of fitness in bloodstream forms (3 days) | alsford |
Tb11.02.5420 | Trypanosoma brucei | significant loss of fitness in bloodstream forms (6 days) | alsford |
Tb11.02.5420 | Trypanosoma brucei | no significant loss or gain of fitness in procyclic forms | alsford |
Tb11.02.5420 | Trypanosoma brucei | no significant loss or gain of fitness in differentiation of procyclic to bloodstream forms | alsford |
Tb11.01.0170 this record | Trypanosoma brucei | no significant loss or gain of fitness in bloodstream forms (3 days) | alsford |
Tb11.01.0170 this record | Trypanosoma brucei | no significant loss or gain of fitness in bloodstream forms (6 days) | alsford |
Tb11.01.0170 this record | Trypanosoma brucei | no significant loss or gain of fitness in procyclic forms | alsford |
Tb11.01.0170 this record | Trypanosoma brucei | no significant loss or gain of fitness in differentiation of procyclic to bloodstream forms | alsford |
b2764 | Escherichia coli | non-essential | goodall |
CELE_K10D2.6 | Caenorhabditis elegans | embryonic lethal | wormbase |
CELE_K10D2.6 | Caenorhabditis elegans | larval arrest | wormbase |
CELE_K10D2.6 | Caenorhabditis elegans | slow growth | wormbase |
CELE_K10D2.6 | Caenorhabditis elegans | sterile | wormbase |
YHR042W | Saccharomyces cerevisiae | inviable | yeastgenome |
PBANKA_0824100 | Plasmodium berghei | Essential | plasmo |
TGME49_219630 | Toxoplasma gondii | Probably essential | sidik |
yeastgenome | Systematic deletion of yeast genes | Saccharomyces Genome Database |
wormbase | C. elegans RNAi experiments | WormBase web site, http://www.wormbase.org, release WS170 |
blattner | Systematic mutagenesis of the E. coli (MG1655) genome | J Bacteriol 2004, 186:4921-4930 |
shigen | Profiling of E. coli Chromosome (PEC) | National Institute of Genetics, Japan |
nmpdr | Genome-scale essentiality datasets from published studies (M. tuberculosis) | National Microbial Pathogen Data Resource |
alsford | High-throughput phenotyping using parallel sequencing of RNA interference targets in the African trypanosome | Genome Res 2011, 21:915-924 |
keio | Systematic single-gene knock-out mutants of E. coli K12 | The Keio Collection |
gerdes | Experimental determination and system-level analysis of essential genes in E. coli MG1655 | Gerdes et al., J Bacteriol. 2003 185:5673-84 |
neb | C. elegans RNAi phenotypes | Data obtained from Wormbase WS150, curated by K. Chaudary and T. Carlow, New England Biolabs |
Affected Entity | Phenotypic quality | Occurs in | Occurs at | Evidence | Observed in | Drugs/Inhibitors |
---|---|---|---|---|---|---|
cell proliferation (GO:0008283) | normal (PATO:0000461) | bloodstream stage trypomastigotes (PLO:0027) | inferred from RNAi experiment (ECO:0000019) | No drug identifiers listed for this gene. | ||
Annotator: | fernan@iib.unsam.edu.ar. | Comment: | normal cell proliferation (no significant loss or gain of fitness) in bloodstream forms (stage 6 days). | References: | 21363968 | |
cell proliferation (GO:0008283) | normal (PATO:0000461) | procyclic (PLO:0034) | inferred from RNAi experiment (ECO:0000019) | No drug identifiers listed for this gene. | ||
Annotator: | fernan@iib.unsam.edu.ar. | Comment: | normal cell proliferation (no significant loss or gain of fitness) in differentiation of procyclic to bloodstream forms . | References: | 21363968 |
In TDR Targets, information about phenotypes that are caused by drugs, or by genetic manipulation of cells (e.g. gene knockouts or knockdowns) is manually curated from the literature. These descriptions help to describe the potential of the target for drug development. If no information is available for this gene or if the information is incomplete, this may mean that i) the papers containing this information either appeared after the curation effort for this organism was carried out or they were inadvertently missed by curators; or that ii) the curation effort for this organism has not yet started.
In any case, if you have information about papers containing relevant validation data for this target, please contact us.
Druggability index (range: 0 to 1): 0.3
10 literature references were collected for this gene.